Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. 1998

D S Bruce, and E S Woodle, and K A Newell, and J M Millis, and D C Cronin, and G E Loss, and H P Grewal, and C T Siegel, and S Pellar, and M A Josephson, and J R Thistlethwaite
Department of Surgery, University of Chicago, Illinois 60637, USA.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D009173 Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. Cellcept,Mycophenolate Mofetil,Mycophenolate Mofetil Hydrochloride,Mycophenolate Sodium,Mycophenolic Acid Morpholinoethyl Ester,Myfortic,RS 61443,RS-61443,Sodium Mycophenolate,Mofetil Hydrochloride, Mycophenolate,Mofetil, Mycophenolate,Mycophenolate, Sodium,RS61443
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

D S Bruce, and E S Woodle, and K A Newell, and J M Millis, and D C Cronin, and G E Loss, and H P Grewal, and C T Siegel, and S Pellar, and M A Josephson, and J R Thistlethwaite
February 2002, Transplantation proceedings,
D S Bruce, and E S Woodle, and K A Newell, and J M Millis, and D C Cronin, and G E Loss, and H P Grewal, and C T Siegel, and S Pellar, and M A Josephson, and J R Thistlethwaite
June 1998, Transplantation proceedings,
D S Bruce, and E S Woodle, and K A Newell, and J M Millis, and D C Cronin, and G E Loss, and H P Grewal, and C T Siegel, and S Pellar, and M A Josephson, and J R Thistlethwaite
August 1998, Transplantation proceedings,
D S Bruce, and E S Woodle, and K A Newell, and J M Millis, and D C Cronin, and G E Loss, and H P Grewal, and C T Siegel, and S Pellar, and M A Josephson, and J R Thistlethwaite
June 2018, Clinical transplantation,
D S Bruce, and E S Woodle, and K A Newell, and J M Millis, and D C Cronin, and G E Loss, and H P Grewal, and C T Siegel, and S Pellar, and M A Josephson, and J R Thistlethwaite
February 1999, Clinical transplantation,
D S Bruce, and E S Woodle, and K A Newell, and J M Millis, and D C Cronin, and G E Loss, and H P Grewal, and C T Siegel, and S Pellar, and M A Josephson, and J R Thistlethwaite
January 1999, Transplantation proceedings,
D S Bruce, and E S Woodle, and K A Newell, and J M Millis, and D C Cronin, and G E Loss, and H P Grewal, and C T Siegel, and S Pellar, and M A Josephson, and J R Thistlethwaite
February 1999, Transplantation,
D S Bruce, and E S Woodle, and K A Newell, and J M Millis, and D C Cronin, and G E Loss, and H P Grewal, and C T Siegel, and S Pellar, and M A Josephson, and J R Thistlethwaite
January 2003, Clinical transplantation,
D S Bruce, and E S Woodle, and K A Newell, and J M Millis, and D C Cronin, and G E Loss, and H P Grewal, and C T Siegel, and S Pellar, and M A Josephson, and J R Thistlethwaite
January 1997, Transplantation proceedings,
D S Bruce, and E S Woodle, and K A Newell, and J M Millis, and D C Cronin, and G E Loss, and H P Grewal, and C T Siegel, and S Pellar, and M A Josephson, and J R Thistlethwaite
June 1998, Transplantation proceedings,
Copied contents to your clipboard!